Choi E, Kim H, Park E, Song S, Phan T, Nam M
Biomol Ther (Seoul). 2023; 31(2):219-226.
PMID: 36782271
PMC: 9970839.
DOI: 10.4062/biomolther.2023.004.
Mohammadi F, Visagan S, Gross S, Karginov L, Lagarde J, Heiser L
Commun Biol. 2022; 5(1):1258.
PMID: 36396800
PMC: 9671968.
DOI: 10.1038/s42003-022-04208-9.
Matsui J, Perlow H, Ritter A, Upadhyay R, Raval R, Thomas E
Biomedicines. 2022; 10(7).
PMID: 35885067
PMC: 9313399.
DOI: 10.3390/biomedicines10071763.
Imai H, Saijo K, Komine K, Otsuki Y, Ohuchi K, Sato Y
Cancer Manag Res. 2019; 11:7953-7965.
PMID: 31686910
PMC: 6709792.
DOI: 10.2147/CMAR.S215697.
Provenzano S, Hindi N, Morosi C, Ghilardi M, Collini P, Casali P
Clin Sarcoma Res. 2015; 5:9.
PMID: 25793102
PMC: 4365557.
DOI: 10.1186/s13569-015-0025-z.
Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma.
Kuribayashi K, Miyata S, Fukuoka K, Murakami A, Yamada S, Tamura K
Mol Clin Oncol. 2014; 1(4):639-642.
PMID: 24649221
PMC: 3916204.
DOI: 10.3892/mco.2013.118.
Synthesis and in vitro evaluation of novel acyclic and cyclic nucleoside analogs with a thiadiazole ring.
Zhao Y, McCarthy P, Parkanyi C
ISRN Org Chem. 2013; 2013:159164.
PMID: 24052860
PMC: 3767340.
DOI: 10.1155/2013/159164.
Gemcitabine eliminates double minute chromosomes from human ovarian cancer cells.
Yu L, Zhao Y, Quan C, Ji W, Zhu J, Huang Y
PLoS One. 2013; 8(8):e71988.
PMID: 23991020
PMC: 3750019.
DOI: 10.1371/journal.pone.0071988.
A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study.
Park J, Lee C, Lee S, Jung C, Kim S, Kwon H
Cancer Res Treat. 2010; 36(1):62-7.
PMID: 20396567
PMC: 2855110.
DOI: 10.4143/crt.2004.36.1.62.
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M
Cancer Invest. 2009; 28(2):172-80.
PMID: 19968494
PMC: 3565222.
DOI: 10.3109/07357900903095722.
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.
Xanthopoulos A, Bauer T, Blum T, Kollmeier J, Schonfeld N, Serke M
J Occup Med Toxicol. 2008; 3:34.
PMID: 19091133
PMC: 2621228.
DOI: 10.1186/1745-6673-3-34.
Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens.
Coskun U, Kaya A, Buyukberber S, Benekli M, Uner A, Dikilitas M
Med Oncol. 2008; 25(2):133-6.
PMID: 18488154
DOI: 10.1007/s12032-007-9005-3.
Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study.
Fabi A, Mirri A, Felici A, Vidiri A, Pace A, Occhipinti E
J Neurooncol. 2007; 87(1):79-84.
PMID: 17987263
DOI: 10.1007/s11060-007-9489-x.
Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma.
Marsh R, George T
Curr Gastroenterol Rep. 2006; 8(2):111-20.
PMID: 16533473
DOI: 10.1007/s11894-006-0006-8.
Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin.
Li X, Tanaka K, Sun J, Filipski E, Kayitalire L, Focan C
Br J Cancer. 2005; 92(9):1684-9.
PMID: 15841076
PMC: 2362038.
DOI: 10.1038/sj.bjc.6602564.
Gemcitabine in non-small cell lung cancer (NSCLC).
Manegold C, Zatloukal P, Krejcy K, Blatter J
Invest New Drugs. 2000; 18(1):29-42.
PMID: 10830139
DOI: 10.1023/a:1006327729228.
Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
Van Kooten M, Traine G, Cinat G, Cazap E, Comba A, Vicente H
Br J Cancer. 1999; 81(5):846-9.
PMID: 10555756
PMC: 2374290.
DOI: 10.1038/sj.bjc.6690774.
Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
Noble S, Goa K
Drugs. 1997; 54(3):447-72.
PMID: 9279506
DOI: 10.2165/00003495-199754030-00009.
Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels.
Pollera C, Ceribelli A, Crecco M, Oliva C, Calabresi F
Invest New Drugs. 1997; 15(2):115-21.
PMID: 9220290
DOI: 10.1023/a:1005817024382.
Gemcitabine and radiosensitization in human tumor cells.
Shewach D, Lawrence T
Invest New Drugs. 1996; 14(3):257-63.
PMID: 8958180
DOI: 10.1007/BF00194528.
